System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Publications

Journal Article Review Epublish 3 citations

PubMed: 38542491 DOI: 10.3390/ijms25063519

Non-Invasive Biomarkers for Diagnosis, Risk Prediction, and Therapy Guidance of Glomerular Kidney Diseases: A Comprehensive Review.

Int J Mol Sci 25(6)

Authors: Lorenzo Catanese, Harald Rupprecht, Tobias B Huber, Maja T Lindenmeyer, Felicitas E Hengel, Kerstin Amann, Ralph Wendt, Justyna Siwy, Harald Mischak, Joachim Beige

Affiliations

  • Department of Nephrology, Angiology and Rheumatology, Klinikum Bayreuth GmbH, 95445 Bayreuth, Germany.
  • Kuratorium for Dialysis and Transplantation (KfH) Bayreuth, 95445 Bayreuth, Germany.
  • Department of Nephrology, Medizincampus Oberfranken, Friedrich-Alexander-University Erlangen-Nürnberg, 91054 Erlangen, Germany.
  • III Department of Medicine, University Medical Center Hamburg-Eppendorf, 20251 Hamburg, Germany.
  • Department of Nephropathology, Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nürnberg, 91054 Erlangen, Germany.
  • Division of Nephrology, St. Georg Hospital, 04129 Leipzig, Germany.
  • Mosaiques Diagnostics GmbH, 30659 Hannover, Germany.
  • Department of Internal Medicine II, Martin-Luther-University Halle-Wittenberg, 06108 Halle, Germany.
  • Kuratorium for Dialysis and Transplantation (KfH) Leipzig, 04129 Leipzig, Germany.

Abstract

Effective management of glomerular kidney disease, one of the main categories of chronic kidney disease (CKD), requires accurate diagnosis, prognosis of progression, assessment of therapeutic efficacy, and, ideally, prediction of drug response. Multiple biomarkers and algorithms for the assessment of specific aspects of glomerular diseases have been reported in the literature. Though, the vast majority of these have not been implemented in clinical practice or are not available on a global scale due to limited access, missing medical infrastructure, or economical as well as political reasons. The aim of this review is to compile all currently available information on the diagnostic, prognostic, and predictive biomarkers currently available for the management of glomerular diseases, and provide guidance on the application of these biomarkers. As a result of the compiled evidence for the different biomarkers available, we present a decision tree for a non-invasive, biomarker-guided diagnostic path. The data currently available demonstrate that for the large majority of patients with glomerular diseases, valid biomarkers are available. However, despite the obvious disadvantages of kidney biopsy, being invasive and not applicable for monitoring, especially in the context of rare CKD etiologies, kidney biopsy still cannot be replaced by non-invasive strategies.

MeSH

Diagnosis, Risk, Prognosis, Kidney Diseases, Biomarkers, Therapeutics, Biopsy

Cited by